Information about Cyklokapron Injection (Tranexamic Acid)
Cyklokapron Injection is a sterile injectable form of tranexamic acid, designed for use in clinical settings. Tranexamic acid is an antifibrinolytic agent that helps prevent excessive bleeding by inhibiting the breakdown of fibrin, a key protein in blood clot formation.
Product Highlights
To control bleeding following major surgical procedures, including orthopedic and dental surgeries.
Used to manage bleeding in trauma patients, especially in emergency settings.
For acute management of heavy menstrual bleeding when oral administration is not suitable.
Assists in controlling bleeding in patients with hemophilia or other bleeding disorders.
Key Ingredient
Tranexamic Acid
Key Benefits
Provides rapid control of bleeding, particularly useful in surgical and trauma situations.
Allows for controlled and precise administration in a clinical setting.
Can decrease the need for blood transfusions by minimizing bleeding.
Acts quickly to address acute bleeding situations.
Direction of Use
Administered by healthcare professionals. The dosage and administration method can vary based on the clinical condition being treated and the patient's response.
Bolus Injection: Typically given as a slow IV push over a specified period.
Infusion: Administered via slow infusion, which may be continuous or intermittent, depending on the treatment protocol.
Renal Impairment
For patients with impaired renal function, the following dosages are recommended.
Serum creatinine (micromol/L)
eGFR (mL/min/1.73m2 )
Dose IV
Dose Orally
Dose frequency
120-249
60-89
10 mg/kg
15 mg/kg
Twice daily
250-500
30- 59
10 mg/kg
15 mg/kg
Daily
>500
< 29
5 mg/kg
7.5 mg/kg
Daily
Adult Cardiac Surgery
eGFR
(mL/min/1.73m2)
Dosage adjustment for Cyklokapron solution for injection
Loading
Prime
Infusion
60-89
15 mg/kg
0.6 mg/kg
3.75 mg/kg/h
30- 59
15 mg/kg
0.6 mg/kg
2.5 mg/kg/h
< 29
15 mg/kg
0.6 mg/kg
1.25 mg/kg/h
Safety Concerns
May include nausea, vomiting, headache, dizziness, or rash.
Rare but serious side effects include thromboembolic events such as deep vein thrombosis or pulmonary embolism due to increased clotting tendency.
Regular monitoring of clotting parameters and kidney function is recommended, especially in patients with pre-existing conditions or those on prolonged therapy.
Avoid Cyklokapron Injection (Tranexamic Acid) If
History of hypersensitivity or allergic reactions to tranexamic acid or any component of the injection.
Conditions such as deep vein thrombosis, pulmonary embolism, or other blood clotting disorders.
Because of the risk of drug accumulation and potential adverse effects.
Use during pregnancy or lactation should be approached with caution and under the guidance of a healthcare provider.
